The robots are preparing Thanksgiving meal boxes – BetaBoston

Robots at Berkshire Greys innovation lab in Bedford have been busy picking up cans of green beans and packets of corn bread mix, placing the items into cardboard boxes as they shuffle down an artificial intelligence-directed assembly line.

This year, the robotics company is using its technology as part of a partnership with two food assistance nonprofits to provide Thanksgiving meals to more than 4,000 families as the pandemic heightens the need for assistance. Already, Berkshire Grey robots have packed tens of thousands of pounds of donated food into boxes.

The system manages the inventory and knows how many of each [item] has to go in each outbound box, said Tom Wagner, chief executive of Berkshire Grey, in an interview. On one pass it might do green beans, on another pass it might do kidney beans, maybe the stuffing...at any given moment it is completing orders and starting new ones.

Berkshire Greys robotics system is typically used by retailers and grocery chains to automate their fulfillment processes.

Working with the Greater Boston Food Bank and City Harvest in New York, the company hopes to lessen the workload for volunteers at food banks, who often assemble donation boxes during the holiday season. Berkshire Grey is calling the initiative Picking With Purpose.

Its a couple people operating a system versus many people manually sorting the goods, Wagner said, adding that the robots work at a comparable speed to humans. The more important thing is that it removes the labor need for the food bank.

Catherine DAmato, chief executive of the Greater Boston Food Bank, said the partnership comes as food insecurity in Massachusetts has increased at a higher rate than in any other state during the health crisis. In a press release, she said the partnership with Berkshire Grey is a promising innovation and will fill a critical need this holiday season, and beyond.

Berkshire Grey first considered using its technology to assemble donation boxes several years ago, but as a smaller business, we just wouldnt have been able to support this, Wagner said. Now, with $265 million in new funding it raised earlier this year, he said he hopes to make the philanthropic effort a regular occurrence, expanding to more cities as it attracts more partners.

In addition to its Bedford headquarters, the company also has a facility in Lexington.

Anissa Gardizy can be reached at anissa.gardizy@globe.com. Follow her on Twitter @anissagardizy8.

See the original post:

The robots are preparing Thanksgiving meal boxes - BetaBoston

Logistics Robots Market to Witness Massive Growth by 2026 – The Daily Philadelphian

A study published on COVID-19 Outbreak-Global Logistics Robots Market, includes exploratory survey, qualitative commentary on changing market dynamics with market sizing and estimates for 18+ Global Countries, business segments and applications. The identification of hot and emerging players is completed by profiling 50+ Industry players; some of the profiled players are Fanuc India Private Limited, ABB Robotics, Asic Robotics AG, Clearpath Inc (OTTO Motors), KION Group, Denso Wave, Kawasaki Heavy Industries, Ltd., Toshiba Corporation, IAM Robotics, Kuka AG, Amazon Robotics, DAIFUKU Co, Ltd & Yaskawa America, Inc.

Get Inside Scoop of the report, request for sample @:https://www.htfmarketreport.com/sample-report/2875836-covid-19-outbreak-global-logistics-robots-industry-market

Latest analysis highlights high growth emerging players and leaders by market share that are currently attracting exceptional attention. It also encourages executives and managers to evaluate deeply complementary research metric. The assessments also offer insight into the share and size of varioussegments in the COVID-19 Outbreak- Logistics Robots market. The scope of the study includes market break-up or segmentation as follows:

Type:, Robotic arms, Unmanned aerial vehicles (UAV), Unmanned ground vehicles (UGV) & Others

Application / End Users:Warehouse, Outdoor, Factory & Others

Early buyers are entitled to receive 10-25% discount on standard version of report or 20% customization on reports at no added cost. Get more details @https://www.htfmarketreport.com/request-discount/2875836-covid-19-outbreak-global-logistics-robots-industry-market

The study cites examples of various market development activities and business strategies that Industry players are taking to overcome economic slowdown and to match demand supply gap. A detailed company profile, Main Business Information, SWOT Analysis, Sales, Revenue, Average Price, Gross Margin and % Market Share of select players would be available in the study.

Extracts from Table of Content.

Chapter 4 COVID-19 Outbreak-Global Logistics Robots Market Landscape (2015-2026)4.1 Market Overview4.2 Classification/Types4.3 Application/End Users

Chapter 5 COVID-19 Outbreak- Logistics Robots Market Dynamics5.1 Introduction5.2 Drivers5.3 Restraints5.4 Opportunities5.5 Threats

Chapter 6 COVID-19 Outbreak- Logistics Robots Market Sizing & Estimates by Revenue, Sales Volume (2015-2026)6.1. North America6.1.1. United States6.1.2. Canada6.1.3. Mexico6.1.4. North America by Type [, Robotic arms, Unmanned aerial vehicles (UAV), Unmanned ground vehicles (UGV) & Others]6.1.5 North America by Application [Warehouse, Outdoor, Factory & Others]

6.2. South America6.2.1. Brazil6.2.2. Argentina6.2.3. Rest of South America6.2.4. South America by Type [, Robotic arms, Unmanned aerial vehicles (UAV), Unmanned ground vehicles (UGV) & Others]6.2.5 South America by Application [Warehouse, Outdoor, Factory & Others]

6.3. Asia Pacific6.3.1. China6.3.2. Japan6.3.3. India6.3.4. South Korea6.3.5. Taiwan6.3.6. Australia6.3.7. Rest of Asia-Pacific6.3.8 Asia Pacific by Type [, Robotic arms, Unmanned aerial vehicles (UAV), Unmanned ground vehicles (UGV) & Others]6.3.9. Asia Pacific by Application [Warehouse, Outdoor, Factory & Others]

6.4. Europe6.4.1. Germany6.4.2. France6.4.3. Italy6.4.4. United Kingdom6.4.5. BeNeLux6.4.6. Rest of Europe6.4.7 Europe by Type [, Robotic arms, Unmanned aerial vehicles (UAV), Unmanned ground vehicles (UGV) & Others]6.4.8. Europe by Application [Warehouse, Outdoor, Factory & Others]

6.5. MEA6.5.1. Middle East6.5.2. Africa

continued

Read Detailed Index of full Research Study at @https://www.htfmarketreport.com/reports/2875836-covid-19-outbreak-global-logistics-robots-industry-market

Furthermore, the years considered for the study are as follows:Historical year 2015-2019Base year 2019Forecast period** 2020 to 2026 [** unless otherwise stated]

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Africa, Europe or Southeast Asia or Just Eastern Asia.

Buy Single User License of this Premium Report @:https://www.htfmarketreport.com/buy-now?format=1&report=2875836

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

Follow this link:

Logistics Robots Market to Witness Massive Growth by 2026 - The Daily Philadelphian

The Worldwide Personal Robots Industry is Expected to Grow at a CAGR of 7.8% Between 2020 and 2030 – GlobeNewswire

Dublin, Nov. 20, 2020 (GLOBE NEWSWIRE) -- The "Personal Robots Market Research Report: By Offering, Type - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

At the present time, the world has become largely dependent on technology, and novel devices are being developed continuously for making the loves of human easier. It is due to this that the demand for personal robots is projected to increase in the coming years. The robotics market has been witnessing significant growth, particularly in the service and private sectors, since the past few years. This can be majorly attributed to the technological advancements.

Owing to these factors, the global personal robots market is projected to grow considerably in the years to come. A major reason leading to the high demand for these robots is their declining prices. Reduced prices of these devices are encouraging more and more people to buy them. The industry has been witnessing 2-9% yearly decline in price. This will further increase the affordability of these robots in emerging economies. Manufacturers are further trying to produce cheaper models for penetrating low-income countries.

These days, manufacturers have further started working on developing personal robots equipped with AI. The technology has enabled personal robots to sense, navigate, and calculate their response on the input received accordingly. The robots learn to perform their tasks from human beings from these responses, via machine learning. Manufacturers are further investing in new technologies for dealing with the rising competition in the domain, which is expected to result in the growth of the market.

The personal robots market is projected to generate a revenue of $51.5 billion in 2030, increasing from $21.5 billion in 2019, progressing at a 7.8% CAGR during the forecast period (2020-2030). On the basis of type, the market is categorized into security robots, personal transportation robots, companion robots, cleaning robots, handicap assistance robots, educational robots, and entertainment & toy robots, out of which, the cleaning robots category held the largest share of the market during the historical period (2014-2019).

These robots are used commonly in households, since they assist in daily chores and make the lives of their owners easier. The acceptance for these robots is further increasing rapidly in emerging countries, owing to their decreasing prices. The companion robots category is predicted to witness the highest CAGR during the forecast period, as they are widely becoming the missing companion in the solitary lives of people. It has been observed that one in every five citizens remains a bachelor in their lives, which is why, the demand for companion robots is predicted to increase in the coming years.

Geographically, the European region held the major share of the personal robots market during the historical period, as per a report by the publisher. The region has already been holding a prominent position in the overall robotics industry, which is why, the demand for personal robots is also high in the region. The Asia-Pacific region is expected to witness the fastest growth during the forecast period.

Key Topics Covered:

Chapter 1. Research Background1.1 Research Objectives1.2 Market Definition1.3 Research Scope1.3.1 Market Segmentation by Offering1.3.2 Market Segmentation by Type1.3.3 Market Segmentation by Geography1.3.4 Analysis Period1.3.5 Market Data Reporting Unit1.3.5.1 Volume1.3.5.2 Value1.4 Key Stakeholders

Chapter 2. Research Methodology2.1 Secondary Research2.1.1 Paid2.1.2 Unpaid2.2 Primary Research2.2.1 Breakdown of Primary Research Respondents2.2.1.1 By region2.2.1.2 By industry participant2.2.1.3 By company type2.3 Market Size Estimation2.4 Data Triangulation2.5 Currency Conversion Rates2.6 Assumptions for the Study

Chapter 3. Executive Summary3.1 Voice of Industry Experts/KOLs

Chapter 4. Introduction4.1 Definition of Market Segments4.1.1 By Offering4.1.1.1 Hardware4.1.1.2 Software4.1.2 By Type4.1.2.1 Cleaning robots4.1.2.2 Entertainment & toy robots4.1.2.3 Educational robots4.1.2.4 Handicap assistance robots4.1.2.5 Companion robots4.1.2.6 Personal transportation robots4.1.2.7 Security robots4.1.2.8 Others4.2 Value Chain Analysis4.3 Market Dynamics4.3.1 Trends4.3.1.1 Open software platform for personal robotics4.3.1.2 Emergence of personal robots with AI4.3.1.3 Entry of new companies in personal robots market4.3.2 Drivers4.3.2.1 Declining price of personal robots4.3.2.2 Aging population in developed countries4.3.2.3 Increasing demand for mobile robots4.3.2.4 Impact analysis of drivers on market forecast4.3.3 Restraints4.3.3.1 Technical complexity coupled with security concerns in personal robots4.3.3.2 Lack of skilled professionals4.3.3.3 Impact analysis of restraints on market forecast4.3.4 Opportunities4.3.4.1 Growing demand for low-cost cleaning robots in developing countries4.3.4.2 Growing demand for "care-bot" and other robots from Japan4.4 Impact of COVID-19 on Personal Robots Market4.4.1 Current scenario4.4.2 COVID-19 scenario4.4.3 Future scenario4.5 Porter's Five Forces Analysis4.5.1 Bargaining Power of Buyers4.5.2 Bargaining Power of Suppliers4.5.3 Intensity of Rivalry4.5.4 Threat of New Entrants4.5.5 Threat of Substitutes

Chapter 5. Global Market Size and Forecast5.1 By Offering5.2 By Type5.3 By Region

Chapter 6. North America Market Size and Forecast6.1 By Offering6.2 By Type6.3 By Country

Chapter 7. Europe Market Size and Forecast7.1 By Offering7.2 By Type7.3 By Country

Chapter 8. APAC Market Size and Forecast8.1 By Offering8.2 By Type8.3 By Country

Chapter 9. LATAM Market Size and Forecast9.1 By Offering9.2 By Type9.3 By Country

Chapter 10. MEA Market Size and Forecast10.1 By Offering10.2 By Type10.3 By Country

Chapter 11. Major Markets for Personal Robots11.1 U.S. Personal Robots Market11.1.1 By Type11.2 Germany Personal Robots Market11.2.1 By Type11.3 China Personal Robots Market11.3.1 By Type

Chapter 12. Competitive Landscape12.1 List of Players and Their Offerings12.2 Ranking of Key Players12.2.1 Global Personal Robots Market Key Players Analysis12.3 Strategic Developments of Market Players12.3.1 Mergers & Acquisitions12.3.2 Product Launches12.3.3 Partnerships12.3.4 Geographic Expansion

Chapter 13. Company Profiles13.1 F&P Robotics AG13.1.1 Business Overview13.1.2 Product and Service Offerings13.2 Segway Inc.13.2.1 Business Overview13.2.2 Product and Service Offerings13.3 Neato Robotics Inc.13.3.1 Business Overview13.3.2 Product and Service Offerings13.4 ZMP Inc.13.4.1 Business Overview13.4.2 Product and Service Offerings13.5 iRobot Corporation13.5.1 Business Overview13.5.2 Product and Service Offerings13.5.3 Key Financial Summary13.6 Ecovacs Robotics Inc.13.6.1 Business Overview13.6.2 Product and Service Offerings13.7 Sony Corporation13.7.1 Business Overview13.7.2 Product and Service Offerings13.7.3 Key Financial Summary13.8 Honda Motor Co. Ltd.13.8.1 Business Overview13.8.2 Product and Service Offerings13.8.3 Key Financial Summary13.9 Samsung Electronics Co. Ltd.13.9.1 Business Overview13.9.2 Product and Service Offerings13.9.3 Key Financial Summary13.10 temi USA Inc.13.10.1 Business Overview13.10.2 Product and Service Offerings

Chapter 14. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/fzb5th

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

The rest is here:

The Worldwide Personal Robots Industry is Expected to Grow at a CAGR of 7.8% Between 2020 and 2030 - GlobeNewswire

FBI hires 140 robots to retrieve sensitive information – ZDNet

Imagine the headache of physically retrieving a paper file from a large records room stuffed full of files. Now expand the problem by imagining a 250,000 square foot facility full of 360,000 filing bins stuffed with paper records.

Not interesting enough? Well, these aren't just any files, but sensitive law enforcement records that could be crucial in stopping crimes and vindicating innocent people.

That's the scenario facing administrators of a Winchester, Virginia, retrieval warehouse for FBI files built to consolidate records previously contained within more than 250 FBI field offices around the world. The FBI is famous for its record keeping and has collected billions of pages over its more than a century in existence. The job of building the facility to house about 2 billion of those pages falls to the government's General Services Administration, and it quickly became evident that manual retrieval for all the files in the new facility simply wasn't an option.

Enter the robots -- 140 of them, to be exact. After vetting various solutions, the GSA chose an automated record filing and retrieval system from robotics technology companyAutoStore, which not only streamlines retrieval via radio-controlled robots but also optimizes space by allowing files to be stored in a way that eliminates aisle space. Within the facility, the robots maneuver on an overhead steel grid system to identify, access, and retrieve requested items from any of the 360,000 bins.

"It is a privilege and honor to know our innovative warehouse automation technology serves U.S. government agencies," says Karl Johan Lier, CEO of AutoStore. "With the agility, efficiency and accuracy of AutoStore robots operating within our elegantly sophisticated high-density grid, the FBI will be able to carry out their mission with greater effectiveness and maintain its leadership in vital information management."

Security is obviously a key element of any installation using sensitive information. That includes ensuring the third-party supplier has no access to sensitive information, and the GSA and National Archives and Records Administration vetted several candidates before deciding on a supplier. The AutoStore software tracks record and bin numbers, allowing the robots to work securely without the system supplier having any access to the records themselves. AutoStore is headquartered outside the U.S., with its main offices in Norway.

According to AutoStore, the filing density of the system will help the government save money on rent and free up valuable space. The Virginia complex opened earlier this year and will be fully operational by 2022.

See more here:

FBI hires 140 robots to retrieve sensitive information - ZDNet

Next-Generation Industrial Robotic Capabilities Advanced by Artificial Intelligence – Robotics Tomorrow

As barriers between human activities and robotic capabilities diminish moving beyond the fenced activities of last-generation industrial robots new collaboration and workflow models are bringing humans and robots together in industry.

Case Study from | Wind River

THE CHALLENGE

Emerging instances of AI-enabled cobots, autonomous vehicles, and non-piloted drone operations are part of an expanding array of innovative use cases in industrial robotics. Industrial robotics integrated with AI are predicted to spur market growth by a projected CAGR of more than 15% in coming years, reaching USD 66.48 billion by 2027, according to Fortune Business Insights. As barriers between human activities and robotic capabilities diminish moving beyond the fenced activities of last-generation industrial robots new collaboration and workflow models are bringing humans and robots together in industry. Despite advances, however, expanding the range of use cases for robotics in Industrial IoT (IIoT) environments requires negotiating long-standing technical roadblocks. This includes the challenge of integrating diverse components across heterogeneous networks, employing machine learning to build and operate intelligent systems that adapt to workflows, and implementing responsive, low-latency communication services to interact with robotics systems in real time.

THE APPROACH

Artificial intelligence is critical to new robotics approaches. And rather than augmenting existing machine operations by bolting on AI-driven components, AI-first puts the intelligence at the forefront of the design process to perform at the core of a task. The focus is on building solutions that meld hardware and software to effectively use machine learning and AI-guided functions, performing operations with greater speed, reliability, security, and safety. As with digital transformation, the AI-first approach requires a rethinking of traditional design transforming architectures to satisfy the solution requirements over the full lifecycle, rather than just reorganizing and tinkering with existing solutions. The Wind Riverportfolio, with its multiple solutions and purpose-built embedded components, provides a flexible and agile foundation for meeting this need. Wind River solutions are elements of an extensive roadmap leading to the benefits and enhanced business value promised by todays industrial robotics.

A global leader in delivering software for intelligent connected systems, Wind River offers a comprehensive, end-to-end portfolio of solutions ideally suited to address the emerging needs of IoT, from the secure and managed intelligent devices at the edge, to the gateway, into the critical network infrastructure, and up into the cloud. Wind River technology is found in nearly 2 billion devices and is backed by world-class professional services and award-winning customer support.

Other Articles

How can industrial equipment companies keep pace with the push to economizeand modernize, to be more data-centric, and to provide safety and security in theface of constant innovation?

How can industrial robots gain new abilities that can increase their operational value while remaining safe and secure in a factory collaborating with humans?

With the accelerating growth of the Internet of Things (IoT), it is increasingly important to identify and implement safety-related systems for smart grids, connected vehicles, robotics, industrial control systems, smart factories, and more.

This post does not have any comments. Be the first to leave a comment below.

You must be logged in before you can post a comment. Login now.

Robotmaster delivers unmatched, full-function off-line programming capability for robots - easy programming of precise robot motion control and quick generation of path trajectories of any size, with minimal programmer intervention. Our strong background in CAD/CAM (Computer Aided Manufacturing) software has enabled us to bring a revolutionary approach to programming industrial robots.

Read more from the original source:

Next-Generation Industrial Robotic Capabilities Advanced by Artificial Intelligence - Robotics Tomorrow

Ethical issues regarding robots raised in research – Fruitnet

With automation poised to transform agriculture around the world in the future, researchers fromMonash University in Melbourne, Australia have published what they say is the first-ever analysis of the ethical and policy issues raised by the use of robots in agriculture.

Agriculture employs around 2.5 per cent of the Australia's workforce and is a valuable export, however, according to Professor of Philosophy Robert Sparrow and Philosophy Research Fellow Mark Howard, little attention has been paid to the ethical and policy challenges that will arise as agriculture is increasingly automated.

Together they investigated the prospects for, and likely impacts and ethical and policy implications of, the use of robotics in agriculture in their paper Robots in agriculture: prospects, impacts, ethics, and policy, recently published in the journal, Precision Agriculture.

While there hasnt yet been widespread adoption of robots in farming due to a lack of technological breakthroughs, its anticipated there will be a gradual emergence of technologies for precision farming as well as the use of automation in food processing and packaging, explained Sparrow.

Already we are seeing the development and, increasingly, the adoption of GPS-enabled autonomous tractors and harvesters, robotic milking stations and dairies, robotic fruit and vegetable pickers, drones for rounding up livestock and crop-dusting and automation in slaughterhouses, food handling, processing and packaging all exist, among others.

The authors said with global and local food security facing profound challenges including climate change, soil depletion, loss of biodiversity, water scarcity and population growth, robots could help farmers confront these challenges by improving yield and productivity, while reducing levels of fertiliser and pesticide use, as well as water wastage.

However, they stated the widespread adoption of robots in farming could have negative consequences, including mismanagement of chemicals, soil compaction due to heavy robots and potential food wastage if consumers come to expect standardised or perfect produce.

This could also lead to further standardisation of breeding and creation via genetic modification of crops and livestock better suited to robotic harvest.

There is also a fear that smaller or struggling farms could miss out on the technology and be unable to keep up, leading to a centralisation of ownership in agriculture.

Theres a risk that robots could impact negatively on biodiversity and on the environmental sustainability of agriculture more generally, said Howard. Strong policy that encourages the development of robots that contribute to small-scale, local, and biodiverse agriculture and do not just promote existing unsustainable agricultural practices is a must."

On a positive note, the physically intense labour associated with agriculture work and its seasonal nature could see robots developed for tasks such as weeding, fruit and vegetable picking, food handling and packaging tasks, which could increase productivity and the amount of produce sent to market.

Labour costs could also be reduced, but this would of course mean a reduction in employment opportunities, particularly for those in rural areas where employment opportunities are scarcer.

Researchers said the industry also needed to consider the potential risk that malicious actors might try to hack, or launch cyber-attacks against, the automation on the farms of other nations.

The urgent need to move towards more sustainable agricultural practices while, at the same time, meeting an increased demand for agricultural produce globally, means that there is a strong ethical imperative to explore how robots might be used to advance these goals, noted Sparrow.

The scale of the current global environmental crisis, and the challenge it poses to food security, suggests that every option to try to improve the sustainability of agriculture should be considered.

Authors said a holistic approach to the uptake of robot technology in agriculture was required, firstly to address public concerns and the social and political impacts that may arise, as well as comprehensive consideration of the ethical and policy ramifications of their use.

See original here:

Ethical issues regarding robots raised in research - Fruitnet

Gene experts claim they identified human genes that can protect against Covid-19 – CNBC

COVID-19 Coronavirus molecule, March 24, 2020.

CDC | API | Gamma-Rapho via Getty Images

A team of CRISPR scientists at the New York Genome Center, New York University and Icahn School of Medicine at Mount Sinai said they have identified the genes that can protect human cells against Covid-19, a disease that has infected over 40 million and led to 1 million deaths worldwide.

The discovery comes after an eight-month screen of all 20,000 genes in the human genome led by Dr. Neville Sanjana at the New York Genome Center. Leading virologist at Mount Sinai, Dr. Benjamin tenOever, developed a series of human lung cell models for the coronavirus screening to better understand immune responses to the disease and co-authored the study.

Their study, published online last month by Cell, will appear in the scientific peer-reviewed journal's Jan. 7 print issue.

The goal was two-fold: to identify the genes that make human cells more resistant to SARS-CoV-2 virus; and test existing drugs on the market that may help stop the spread of the disease.

The breakthrough comes at a time when drug makers such as Pfizer, Oxford-AstraZeneca and Moderna are fast-forwarding vaccine and therapeutics to treat Covid-19. On Friday, Pfizer and BioNTech requested emergency authorization from the FDA for their Covid vaccine that contains genetic material called messenger RNA, which scientists expect provokes the immune system to fight the virus.

In order to better understand the complex relationships between host and virus genetic dependencies, the team used a broad range of analytical and experimental methods to validate their results. This integrative approach included genome editing, single-cell sequencing, confocal imaging and computational analyses of gene expression and proteomic datasets.

After intensive research, the scientists and doctors claim they have found 30 genes that block the virus from infecting human cells including RAB7A, a gene that seems to regulate the ACE-2 receptor that the virus binds to and uses to enter the cell. The spike protein's first contact with a human cell is through ACE-2 receptor.

"Our findings confirmed what scientists believe to be true about ACE-2 receptor's role in infection; it holds the key to unlocking the virus," said Dr. tenOever. "It also revealed the virus needs a toolbox of components to infect human cells. Everything must be in alignment for the virus to enter human cells."

The team discovered that the top-ranked genes those whose loss reduces viral infection substantially clustered into a handful of protein complexes, including vacuolar ATPases, Retromer, Commander, Arp2/3, and PI3K. Many of these protein complexes are involved in trafficking proteins to and from the cell membrane.

"We were very pleased to see multiple genes within the same family as top-ranked hits in our genome-wide screen. This gave us a high degree of confidence that these protein families were crucial to the virus lifecycle, either for getting into human cells or successful viral replication," said Dr. Zharko Daniloski, a postdoctoral fellow in the Sanjana Lab and co-first author of the study.

Using proteomic data, they found that several of the top-ranked host genes directly interact with the virus's own proteins, highlighting their central role in the viral lifecycle. The team also analyzed common host genes required for other viral pathogens, such as Zika or H1N1 pandemic influenza.

The research team also identified drugs that are currently on the market for different diseases that they claim block the entry of Covid-19 into human cells by increasing cellular cholesterol. In particular, they found three drugs currently on the market were more than 100-fold more effective in stopping viral entry in human lung cells:

The other five drugs that were tested called PIK-111, Compound 19, SAR 405, Autophinib, ALLN -- are used in research but are not yet branded and used in clinical trials for existing diseases.

Our findings confirmed what scientists believe to be true about ACE-2 receptor's role in infection; it holds the key to unlocking the virus.

Their findings offer insight into novel therapies that may be effective in treating Covid-19 and reveal the underlying molecular targets of those therapies.

The bioengineers in New York were working on other projects with gene-editing technology from CRISPR but quickly pivoted to studying the coronavirus when it swept through the metropolitan area last March. "Seeing the tragic impact of Covid-19 here in New York and across the world, we felt that we could use the high-throughput CRISPR gene editing tools that we have applied to other diseases to understand what are the key human genes required by the SARS-CoV-2 virus," said Dr. Sanjana.

Dr. Neville Sanjana and his team at the New York Genome Center used CRISPR to identify the genes that can protect human cells against Covid-19.

New York Genome Center

As he explained, "current treatments for SARS-CoV-2 infection currently go after the virus itself, but this study offers a better understanding of how host genes influence viral entry and will enable new avenues for therapeutic discovery."

Previously, Dr. Sanjana has applied genome-wide CRISPR screens to identify the genetic drivers of diverse diseases, including drug resistance in melanoma, immunotherapy failure, lung cancer metastasis, innate immunity, inborn metabolic disorders and muscular dystrophy.

"The hope is that the data from this study which pinpoints required genes for SARS-CoV-2 infection could in the future work be combined with human genome sequencing data to identify individuals that might be either more susceptible or more resistant to Covid-19," Dr. Sanjana said.

The New York team is not the first to use CRISPR gene editing techniques to fight Covid-19. Other bioengineering groups at MIT and Stanford have been using CRISPR to develop ways to fight the SARS-CoV-2 and develop diagnostic tools for Covid-19.

The potential for using CRISPR to eliminate viruses has already generated some enthusiasm in the research community. Last year, for example, Excision BioTherapeuticslicenseda technology from Temple University that uses CRISPR, combined with antiretroviral therapy, to eliminate HIV, the virus that causes AIDS.

View original post here:

Gene experts claim they identified human genes that can protect against Covid-19 - CNBC

Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020 – GlobeNewswire

-- Sarepta is honored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community --

-- Rankings based on confidential survey information submitted by employees to independent research company --

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has been named one of TheBoston Globes Top Places to Work in 2020 in the large company category.

The Boston Globes 2020 list recognizes 150 companies and organizations in Massachusetts based on surveys completed by their employees about the workplace, including 40 in the large company category. The survey measured opinions about company direction, execution, connection, management, work, pay and benefits, and engagement. Companies also provided supplemental information about responses to the global pandemic and changes implemented in how teams work.

This recognition reflects the quality of the Sarepta employees, who together have built a positive culture, navigated a challenging environment this year and, both at facilities and from home, remained focused on our daily race to save lives stolen or impacted by rare disease, said Doug Ingram, president and CEO, Sarepta. It is a testament to the resilience, tenacity and commitment of those who work at Sarepta.

Sarepta is committed to engineering precision genetic medicine to reclaim futures otherwise impacted or cut short by ushering in a new era of drug development, with the goal of shortening the time from lab to patient. The Company is building among the worlds largest gene therapy manufacturing capacity, and rethinking access and reimbursement models for revolutionary new treatments. Sareptas purpose-driven culture, where patient-focus is central to the values that shape how work is done, was resoundingly echoed by its people as a key attribute that contributed to its top ranking. Additionally, Sarepta fosters an environment that encourages its people to bring their whole selves to work and share ideas that support the entire workforce and the patient community it serves.

As the Company adjusted during the pandemic, several initiatives and new benefits were implemented as a result of employee feedback:

At Sarepta, a vision for the possibilities of pioneering science to redefine the future of medicine, and advance treatment options for patients, is shared by all. Individuals who are inspired by the opportunity to toss aside convention and break down barriers to radically change the future of medicine are encouraged to explore employment opportunities at http://www.sarepta.com.

About Sarepta TherapeuticsAt Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.comor follow us onTwitter,LinkedIn,InstagramandFacebook.

Source:Sarepta Therapeutics, Inc.

Media and Investors:Sarepta Therapeutics, Inc. Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.com Media: Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com

Excerpt from:

Sarepta Therapeutics Named One of The Boston Globe's Top Places to Work 2020 - GlobeNewswire

Genome Medical Reaches 90 Million Covered Lives in US – PRNewswire

As a nationwide telehealth medical practice, Genome Medical has assembled an extensive team of clinical genetic experts, including board-certified genetic counselors, medical geneticists and other specialists. This team delivers education, risk assessment, access to genetic testing and specialty care referrals -- all through virtual visits. During the COVID-19 pandemic, when two out of five Americans have avoided or delayed medical care1, access to safe virtual services is essential to ensure people at greatest risk are receiving the care they need. Genetic services support the diagnosis and care management of hereditary conditions and the identification of patients at an elevated risk for disease.

Some of the largest payers in the United States are recognizing the critical role geneticists and genetic counselors play. Their members can now self-refer and get in-network access to Genome Medical's genetic experts, and the payer's contracted providers can also make in-network referrals for their patients.

The 90 million covered lives are across multiple payers, including (in part):

"Genome Medical brings together telemedicine and genomics to tackle the rising need for genetic experts to guide patients and providers in making appropriate decisions around 1) who should get genetic testing, 2) which test is optimal and 3) how clinical care should be changed based on test results," said Steven B. Bleyl, M.D., Ph.D., chief medical officer of Genome Medical. "Patients can be seen sooner, and through telehealth, we extend the reach of genetic services to rural communities and underserved areas that have less access to in-person care. Genome Medical is a flexible and cost-effective solution for payers and their members."

Genome Medical can see 85% of cancer patients more quickly than in a traditional clinic setting.2 And in areas like pediatric genetics, where wait times of six months or more for an appointment are common, Genome Medical's growing clinical team can often see patients within a few days. The company's genetic experts are licensed in all 50 states and provide clinical genetics expertise across six major specialty areas: cancer, reproductive health, proactive health, pediatrics/rare disease, pharmacogenomics and cardiovascular genetics. Genome Medical's innovative services are trusted and utilized by health systems, hospitals, testing labs, payors, providers and employers.

Genome Medical is also committed to leveraging advanced technology-enabled solutions to transform the delivery of standard-of-care genetic health services. Beyond wider and accelerated access, the company's technology delivers a 5.5X return on investment in genetic services, while also reducing the cost of care by up to 75 percent.3,4 Its Genome Care DeliveryTM platform creates an efficient and comprehensive experience, including patient engagement and care navigation, risk assessment, self-directed education and informed consent through the Genome Care NavigatorTM, multi-modality patient support, and peer-to-peer provider consultations.

"We are pleased to see health plan partners continue to expand in-network coverage for our genetic health services," said Lisa Alderson, co-founder and CEO of Genome Medical. "It is estimated that tens of millions of patients in the United States meet medical management guidelines for referral to genetics, but most are still being missed. These patients could benefit from the advancements made in utilizing genomics for prevention, diagnosis and treatment. Giving their members access to Genome Medical and telegenetics is a significant step payers are taking in removing historical barriers."

About Genome MedicalGenome Medical is a national telegenomics technology, services and strategy company bringing genomic medicine to everyday care. Through our nationwide network of genetic specialists and efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. We also help health care providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care. We are shepherding in a new era of genomic medicine by creating easy, efficient access to top genetic experts. Genome Medical is headquartered in South San Francisco. To learn more, visit genomemedical.com and follow @GenomeMed.

References

SOURCE Genome Medical

Genetic Counseling & Services from Anywhere | Genome Medical

Continue reading here:

Genome Medical Reaches 90 Million Covered Lives in US - PRNewswire

New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients – PRNewswire

SAN FRANCISCO, Nov. 19, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today presented study findings that show nine percent of patients with pancreatic cancer had genetic changes in DNA damage repair (DDR) genes that would make them eligible for PARP inhibitor therapy or clinical treatment trials. Despite professional guidelines that recommend testing for all pancreatic cancer patients, it remains underutilized in routine care. The study was presented at the National Society of Genetic Counselors 39th Annual Conference.

"New therapeutics have recently become available to treat pancreatic cancer for patients with certain changes in genes such as BRCA1 and BRCA2. Yet despite the availability of these treatments and professional guidelines recommending testing, utilization is still lagging," said Robert Nussbaum, M.D., chief medical officer of Invitae and study author. "Pathogenic variants in these genes are associated with an increased risk of other cancers as well, such as breast, ovarian and prostate cancer, which means that a failure to test patients with pancreatic cancer impacts not only their treatment, but also the health of their families."

Importantly, the study of over 2,000 patients found that 15% of patients with actionable genetic changes reported no family history of cancer, which underscores the limitations of using testing criteria based on reported family history. National Comprehensive Cancer Network (NCCN) guidelines recommend genetic counseling and germline genetic testing for everyone diagnosed with pancreatic cancer as well as their first degree relatives -- approximately 3.5 million individuals in the United States.

In addition to evaluating the clinical relevance of genetic testing results, the study offered sponsored, no-charge testing to patients to evaluate the role of cost as a barrier to testing. Researchers found a small but significant increase (2%) in testing among African-American patients compared to typical rates among patients using health insurance, suggesting reducing cost may increase access to testing among this population.

The research was presented at the virtual annual meeting of the National Society of Genetic Counselors. The full research presentation from Invitae included:

Oral platform presentations:

Poster presentations:

In addition to its scientific presence, Invitae will again partner with NSGC to present the Heart of Genetic Counseling award, which honors excellence in genetic counseling and patient care as recognized by patients. Nominations include stories from patients that highlight both the clinical and personal impact a genetic counselor had on their lives and the lives of their families. This year's award will be presented during a virtual ceremony on Thursday, November 17th. The finalists include:

About Invitae

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website atinvitae.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the implications of the company's study results; and the importance and potential benefits of genetic testing for pancreatic cancer patients. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Contact:

Laura D'Angelo[emailprotected](628) 213-3283

SOURCE Invitae Corporation

http://www.invitae.com

More here:

New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients - PRNewswire

Baylor Genetics Launches Combination Test for COVID-19 and Influenza A and B; Multi-Panel Test Seeks to Address Dilemma of "Overlapping symptoms…

HOUSTON, Nov. 17, 2020 /PRNewswire/ --With the arrival of flu season, Baylor Genetics, a pioneer of genetic testing and precision medicine, has launched the latest combination test for the novel coronavirus, SARS-CoV-2, and Influenza A and B.

"Baylor Genetics created the combination COVID-19 and flu test because the symptoms between the two are so similar, but the treatments are undeniably different," stated Kengo Takishima, President & Chief Executive Officer at Baylor Genetics. "This groundbreaking test, with results available in 48 hours or less, will result in better data and more accurate treatments for these similar, but distinct, viruses."

In response to the global pandemic, Baylor Genetics validated its first test for COVID-19 in June 2020. Once launched, the company continued to focus on innovative efforts to help prevent the spread of the disease. Some of these efforts include unique partnerships with the City of Houston and Rice University. With their latest COVID-19 (SARS-CoV-2) & Flu (Influenza A/B) RT-PCR test, individuals will be able todetermine if they are currently infected with COVID-19 or the flu.

"The clinical presentations of COVID-19 and influenza are similar, and it is difficult to differentiate the two entities on symptoms alone," stated Dr. Christine Eng, Chief Medical Officer and Chief Quality Officer at Baylor Genetics. "This combination test will identify if SARS-CoV-2 or influenza A/B is the culprit, thus helping you and your healthcare provider better direct your care. Of course, it's important to stay proactive this season and get your flu shot if you haven't already."

Since many are traveling during the holidays, it is imperative that individuals know whether they are infected with either COVID-19 or the flu and how to treat each virus. While these respiratory viruses have similar symptoms, their treatments are different. For COVID-19, potential treatment and vaccine options are emerging. For the flu, antiviral medications can help address symptoms and potentially shorten the time an individual is sick. Therefore, it is crucial for individuals to be able to confirm which virus they may be infected with to take the proper next steps to restore their health.

For the COVID-19 and flu combination test, all sample results will be sent to individuals securely and electronically within 48 hours of Baylor Genetics' receiving the sample. In addition, the results will be automatically reported to state officials to track and slow the spread of cases in the local community. With accepted sample types of nasal or nasopharyngeal swab, all of the supplies for testing and returning the kit is provided to the individual.

To learn more about Baylor Genetics' test for COVID-19, visit https://www.baylorgenetics.com/covid19/.

About Baylor GeneticsBaylor Genetics is a joint venture of H.U. Group Holdings, Inc. and Baylor College of Medicine, including the #1 NIH-funded Department of Molecular and Human Genetics. Located in Houston's Texas Medical Center, Baylor Genetics serves clients in 50 states and 16 countries.

To learn more about Baylor Genetics visit http://www.baylorgenetics.com.

SOURCE Baylor Genetics

Read more here:

Baylor Genetics Launches Combination Test for COVID-19 and Influenza A and B; Multi-Panel Test Seeks to Address Dilemma of "Overlapping symptoms...

CHOP Researchers Reverse Severe Lymphatic Disorder in Patient with Noonan Syndrome by Targeting Genetic Pathway – BioSpace

Precise treatment leads to resolution of patient's debilitating symptoms and complete remodeling of her lymphatic system

PHILADELPHIA, Nov. 20, 2020 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) have resolved a severe lymphatic disorder in a girl with Noonan Syndrome that had led to upper gastrointestinal bleeding, fluid collection around the lungs, and numerous surgeries that had been unable to resolve her symptoms. By identifying a genetic mutation along a pathway related to lymphatic vessel development and function, the research team was able to target the pathway using an existing drug they had used in a previous case to remodel a patient's lymphatic system.

The case study, which was published today in Pediatrics, describes a resolution of the patient's symptoms within three months while on the medication.

"This study is quite significant," said first author Yoav Dori, MD, PhD, Director of the Jill and Mark Fishman Center for Lymphatic Disorders at CHOP. "Inhibiting this pathway seems to have sweeping, widespread effects on the lymphatic system. How this process occurs is not fully understood, but is remarkable in its speed and breadth. This gives us a lot of hope for treating other patients with genetic mutations along this same pathway in the future."

The patient described in the paper, Maria, first came to CHOP when she was 14, after experiencing severe anemia due to upper gastrointestinal bleeding, as well as other symptoms including fluid build-up in the cavity around her lungs, chronic fatigue, delayed puberty, and difficulty gaining weight. Maria had been born with Noonan Syndrome, a genetic disorder that prevents normal development in various parts of the body and often results in short stature, heart defects and other physical problems, including an abnormal lymphatic system. Despite aggressive medical therapy elsewhere, Maria continued to bleed internally, and she underwent multiple blood transfusions to try to stabilize her health.

Within two days of transferring to CHOP, the lymphatics team, led by Dori, determined Maria had many lymphatic irregularities, which were leading to internal bleeding and lung problems, so they scheduled Maria's first intervention, a lymphatic embolization procedure that would seal the leaky vessels in her gut.

However, within two months of the procedure, Maria's gastrointestinal bleeding recurred. Over the following 8 months, she underwent two additional procedures, as well as a cauterization procedure to close off some of the blood vessels in her gut, but the benefits of each procedure lasted only about three months before the bleeding and her symptoms returned.

Based on whole exome sequencing done at CHOP's Center for Applied Genomics, the research team learned that Maria had a genetic mutation in the SOS1 gene, which operates along the RAS-MAPK pathway. This pathway involves mitogen-activated protein kinase (MEK), and Maria's mutation caused an overproduction of MEK, which resulted in the uncontrolled proliferation of her lymphatic vessels.

The research team had previously used a MEK inhibitor in another patient with a severe lymphatic disorder with great success. That patient had a mutation in the ARAF gene, which is also on the RAS-MAPK pathway. Within months of beginning treatment with trametinib, a MEK inhibitor, the patient saw a resolution of his symptoms and a complete remodeling of his lymphatic system.

Given that SOS1 operates on the same pathway as ARAF, Jean Belasco, MD, an oncologist in CHOP's Cancer Center who co-led the study, applied for compassionate use of the drug in Maria's case, given the lack of other treatment options.

"The success of trametinib in another patient with a mutation on the RAS-MAPK pathway encouraged us to try this approach, since other procedures and therapies continued to be unsuccessful," Belasco said. "Although we are in the early days of this type of personalized medicine, the hope is that by looking at patients' mutations, we can find more drugs and better care for patients with genetic diseases."

Within three months of starting the drug, Maria's vital signs stabilized. The bleeding stopped, her electrolyte, hemoglobin, and albumin levels returned to normal, and she began to gain weight. Maria's mother noticed that Maria wasn't going through periods of exhaustion anymore, and her pallor improved.

"She looks better than she's ever looked," her mother said. "She looks like a normal teenager. It's like night and day. She's also a lot happier. I think she knew deep down she was dying. The medicine gave her hope."

Hakon Hakonarson, Director of the Center for Applied Genomics and co-author of the paper, said that although Maria's SOS1 mutation is distinctly different than the ARAF mutation seen in the other patient, the drug was equally effective because it targets and blocks the function of MEK. He likened the scenario to a pathway where 15 events need to occur for a cell to function. Maria's SOS1 mutation might occur at step nine, whereas the ARAF mutation might occur at step three, but both genes are on a chain that ultimately passes through a tunnel that leads to phosphorylation and overactivity of MEK. Since both mutations were so-called gain of function mutations, MEK and thus lymphatic activity was overexpressed in both patients. The MEK inhibitor put the brakes on a system in overdrive.

"Remarkable advances in genetics have allowed us to uncover these mutations and cluster them into selective pathways and determine effective therapies based on genetic mutations with very high precision," said Hakonarson. "No one could have guessed that this drug would have worked for Maria without knowing the underlying genetics. This discovery is extremely important because Noonan Syndrome has the biggest patient population with alterations in MEK signaling. Not all Noonan patients will have mutations that respond to this therapy, but a very good number of them will."

He added that the treatment could also benefit patients with other genetic defects, though he noted the ongoing use of the drug treats the symptoms caused by these mutations, but does not fix the gene or cure the underlying condition.

"MEK inhibition has the potential to have significant effects on other organ systems affected by RAS-MAPK gene defects, such as the heart, eyes, skin and the coagulation system," Hakonarson said.

Hakonarson is also part of CHOP's Comprehensive Vascular Anomalies Program (CVAP), a CHOP Frontier Program that uses state-of-the-art genomics and personalized research strategies to determine the causes of complex vascular conditions and identify targeted therapies. The program works closely with the Lymphatic Imaging and Interventions Frontier Program, which is led by Dori. CHOP's Frontier Programs conduct cutting-edge research that translates into advanced clinical care. The CVAP, in particular, draws on the extensive clinical and genomic research capacity within the Cancer Center and Center for Applied Genomics.

Even with the success of the breakthrough treatment pioneered by these programs, it is not entirely clear why MEK inhibitors not only resolve patients' symptoms but also completely remodel their lymphatic systems. Hakonarson said one possibility is that when mutated genes cause uncontrolled growth of the lymphatic system, the body's vessels leak fluid everywhere in the body. When you shut down the unregulated growth, other homeostatic mechanisms that are balancing the system come into effect, so the overreactive cells that were growing out of control die and are replaced by normal cells that gradually build up the lymphatic system.

Whatever the mechanism, Maria's mother said her daughter had no hesitation at being the first patient with Noonan Syndrome to try this treatment to resolve a lymphatic issue.

"Maria saw the value from the beginning," she said. "She saw the value for herself, but she was also thinking of other Noonan kids, some of whom have passed away from lymphatic issues. She was willing and eager."

Dori et al. "Severe Lymphatic Disorder Resolved with MEK Inhibition in a Noonan Patient with SOS1 Mutation," Pediatrics, published online November 20, 2020, doi: 10.1542/2020-000123

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 564-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Natalie SolimeoChildren's Hospital of Philadelphia267-426-6246solimeon@chop.edu

View original content:http://www.prnewswire.com/news-releases/chop-researchers-reverse-severe-lymphatic-disorder-in-patient-with-noonan-syndrome-by-targeting-genetic-pathway-301177697.html

SOURCE Children's Hospital of Philadelphia

Read the original post:

CHOP Researchers Reverse Severe Lymphatic Disorder in Patient with Noonan Syndrome by Targeting Genetic Pathway - BioSpace

Epigenetics and pulmonary diseases in the horizon of precision medicine: a review – DocWire News

This article was originally published here

Eur Respir J. 2020 Nov 19:2003406. doi: 10.1183/13993003.03406-2020. Online ahead of print.

ABSTRACT

Epigenetic mechanisms represent potential molecular routes which could bridge the gap between genetic background and environmental risk factors contributing to the pathogenesis of pulmonary diseases. In patients with chronic obstructive pulmonary disease (COPD), asthma, and pulmonary arterial hypertension (PAH), there is emerging evidence of aberrant epigenetic marks, mainly including DNA methylation and histone modifications which directly mediate reversible modifications to the DNA without affecting the genomic sequence. Post-translational events and microRNAs can be also epigenetically regulated and potentially participate to disease pathogenesis. Thus, novel pathogenic mechanisms and putative biomarkers may be detectable in peripheral blood, sputum, nasal and buccal swabs, or lung tissue. Besides, DNA methylation plays an important role during the early phases of fetal development and may be impacted by environmental exposures, ultimately influencing an individuals susceptibility to COPD, asthma, and PAH later in life. With the advances in omics platforms and the application of computational biology tools, modelling the epigenetic variability in a network framework, rather than as single molecular defects, is providing insights into the possible molecular pathways underlying the pathogenesis of COPD, asthma, and PAH. Epigenetic modifications may have clinical applications as non-invasive biomarkers of pulmonary diseases. Moreover, combining molecular assays with network analysis of epigenomic data may aid in clarifying the multi-stage transition from a pre-disease to disease state, with the goal of improving primary prevention of lung diseases and its subsequent clinical management.We describe epigenetic mechanisms known to be associated with pulmonary diseases and discuss how network analysis could improve our understanding of lung diseases.

PMID:33214212 | DOI:10.1183/13993003.03406-2020

Read the rest here:

Epigenetics and pulmonary diseases in the horizon of precision medicine: a review - DocWire News

Myriad Genetics Announces Global Expansion of Myriad myChoice Tumor Testing in Europe and China – GlobeNewswire

SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad myChoice tumor testing in several European markets and China.

Myriad myChoice CDx is the industrys most clinically-validated genomic instability test. The test enables physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in potentially increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors, including Lynparza (olaparib). A biomarker subgroup analysis of the PAOLA-1 Phase III trial (Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer, 2019) of Lynparza included patients with advanced ovarian cancer and homologous recombination deficient (HRD)-positive tumors as detected by the myChoice test, including those with BRCA gene mutations. The trial showed that Lynparza in combination with bevacizumab maintenance treatment improved progression-free survival to a median of 37.2 months versus 17.7 months for bevacizumab alone in patients with HRD-positive advanced ovarian cancer. Recently, the European Commission authorized use of Lynparza for the first-line maintenance treatment with bevacizumab of patients with HRD-positive advanced ovarian cancer. Lynparza is jointly developed and commercialized by AstraZeneca (LSE/STO/Nasdaq: AZN) and Merck.

As part of the expansion in Europe, Myriad will license and provide technological support to leading pathology institutes in Germany and France. Additionally, Myriad will support European customers by performing testing out of its clinical laboratory at the companys global headquarters in Salt Lake City. Also, the institutes in Europe will perform the tests with Myriads myChoice CDx PLUS assay. Myriad myChoice CDx PLUS is CE-marked in accordance with the In-Vitro Diagnostic Devices Directive (98/79/EC).

Another collaboration in China provides that Myriad will partner with Burning Rock Biotech, a leader in next generation sequencing technology for precision oncology, to provide myChoice for HRD testing in Phase III clinical studies and clinics throughout China. Myriad will provide Burning Rock with access to its proprietary myChoice technology. The partnership with Burning Rock expands global access to myChoice and positions the test as a preferred developmental companion diagnostic in this important drug development category.

These new strategic partnerships with leading companies dedicated to advancing the power of precision medicine, reinforce Myriads commitment to expanding access to genetic insights for more patients than ever before, said Nicole Lambert, president of Myriad Genetic Laboratories. Through close collaboration with innovative laboratories in Europe and with Burning Rock in China, we are bringing the clinical benefits of myChoice testing to additional markets and patients, advancing personalized treatment for patients around the world.

In August 2020, myChoice was exclusively cited and the only named commercial companion diagnostic by the American Society of Clinical Oncology in new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer. The new recommendations, based on clinical trial results, were published in the Journal of Clinical Oncology.

AboutMyriad myChoice Myriad myChoice is the most comprehensive homologous recombination deficiency (HRD) test, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The myChoice test comprises tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions). For more information, visit: https://myriad-oncology.com/mychoice-cdx/

About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website:www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Companys new international collaborations on the myChoice CDx test, including offering the test to European patients, and partnering with pathology institutes in Europe and Burning Rock in China; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Jared Maxwell (801) 505-5027 jmaxwell@myriad.comInvestor Contact: Scott Gleason(801) 584-1143sgleason@myriad.com

Originally posted here:

Myriad Genetics Announces Global Expansion of Myriad myChoice Tumor Testing in Europe and China - GlobeNewswire

Four years after landing in US, graduating ISU senior is on his way to medical school – Iowa State University News Service

Mohamed Elrashed Shogar, graduating in genetics, stands inside a Molecular Biology Building laboratory where he has conducted much of his undergraduate research. Photo by Christopher Gannon. Larger image. All photos and videos were shot following physical distancing guidelines, and with staff wearing face coverings.

AMES, Iowa A headache started Mohamed Shogars journey to a career in medicine.

His mothers relentless headaches forced her to travel more than 900 miles from their home to Sudans capital, Khartoum, for treatment. She never found relief, and it frustrated Shogar, who is graduating from Iowa State University next weekend with a bachelors degree in genetics.

Shes the reason, Shogar said. She motivated me to pursue a career in medicine.

He was also bothered by the physician shortage in his hometown of Al Fashir. Shogar noticed the same physician shortage when he arrived in the United States and again thought, Why not pursue a career in medicine to help them out?

Shogars mother has a Ph.D. and his father is a high school principal. Education was the biggest priority for his family. So, after graduating high school, Shogar came to the U.S. in 2016.

After traveling to Egypt to meet with the U.S. ambassador and receive a green card, Shogar was on his way.

The first time, when I landed in Chicago, I was so overwhelmed, he said. I didnt know what to expect. I didnt know the language or the culture. I had just finished high school, and the future wasnt clear to me.

He headed to Cedar Rapids, where he lived with his cousin for a few months and talked to newfound friends about his educational options in the state. One friend suggested starting out at a community college before heading to a four-year university. So, Shogar enrolled at Kirkwood Community College and took English as a Second Language classes while working full time at the Nordstrom warehouse. He gained medical experience as a phlebotomist at Mercy Medical Center in Cedar Rapids before taking some courses at the University of Iowa.

In 2018, he transferred to Iowa State to finish his genetics degree. At the same time, hes worked as a phlebotomist at Mary Greeley Medical Center.

I wouldnt have done it without the people who helped me out, he said. Im so grateful for them.

During his first semester in Ames, Shogar had to take organic chemistry considered one of the most difficult courses at Iowa State. He struggled during the first exam and felt defeated. But he went to the office of chemistry professor Arthur Winter for help. They talked about college courses generally, and how to study. On Shogars next organic chemistry exam, he received a near-perfect score.

Shogar found community and friendship in his classes as well as student organizations, such as the Sudan United Association and the Minority Association for Pre-Health Students.

He typically travels back to Sudan every winter to visit his family, but with the ongoing COVID-19 pandemic and his post-graduation plans, that visit is on hold. Right now, hes in the midst of the nerve-wracking process of applying to medical schools.

Shogar said going to school and working through the pandemic has been mentally and emotionally draining.

It also had an impact on my education journey, he said. I was not able to shadow and volunteer, which is a very important part in medical school applications.

He also found a mentor in Mark Hargrove, Morrill Professor of biochemistry, biophysics and molecular biology (BBMB), who talked with Shogar about his plans after graduation. To build his research experience, Gordon connected Shogar with Alan DiSpirito, professor of BBMB, whose lab works with methanobactin to study its effects on Wilsons disease, a genetic disorder that causes excessive copper build-up in the body.

This has been an amazing experience, honestly, Shogar said. Its been such a welcoming environment.

The opportunities that I got here, I dont think I would be able to get in Sudan. In terms of the quality of education, I cant even compare it.

View original post here:

Four years after landing in US, graduating ISU senior is on his way to medical school - Iowa State University News Service

Lethal brain infections in mice thwarted by decoy molecule – Washington University School of Medicine in St. Louis

Visit the News Hub

Discovery of receptor, generation of decoy could help contain outbreaks of Venezuelan equine encephalitis virus

Researchers at Washington University School of Medicine in St. Louis have identified a molecule that protects mice from brain infections caused by Venezuelan equine encephalitis virus (VEEV), a mosquito-borne virus notorious for causing fast-spreading, deadly outbreaks in Mexico, Central America and northern South America.

Researchers at Washington University School of Medicine in St. Louis have identified a molecule that protects mice from brain infections caused by Venezuelan equine encephalitis virus (VEEV), a mosquito-borne virus notorious for causing fast-spreading, deadly outbreaks in Mexico, Central America and northern South America. As the climate changes, the virus is likely to expand its range and threaten more countries in the Americas, including the U.S.

Public health officials have struggled to contain such outbreaks in the absence of effective drugs and vaccines. As a potential drug, the molecule described in a paper published Nov. 18 in the journal Nature could serve as a much needed tool to control the deadly virus.

This virus can infect many species of wild mammals, and every few years it jumps from animals to humans via mosquitoes and causes thousands of infections and many deaths, said senior author Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine and a professor of molecular microbiology, and of pathology and immunology. Theres concern that with global warming and population growth, well get more outbreaks.

Once injected under the skin by mosquitoes, the virus homes in on neurons. People start experiencing symptoms such as headache, muscle pain, fatigue, vomiting, nausea, diarrhea, sore throat and fever within a week. In the most serious cases, the virus gets past the blood-brain barrier, causing encephalitis brain inflammation that can be fatal in up to a quarter of patients.

To find the potential drug, Diamond and colleagues including first authors Hongming Ma, PhD, an instructor in medicine, and Arthur S. Kim, PhD, a postdoctoral researcher began by searching for the protein handle on the surface of animal cells that the virus attaches to and uses to get inside cells. A drug that stops the virus from grabbing that handle, the scientists reasoned, could stymie infection and prevent disease.

But first they had to make a form of the virus they could work easily with. During the Cold War, the U.S. and the Soviet Union attempted to weaponize the virus, and it is still classified as a select agent, meaning only certain high-security labs are allowed to work with it. So instead, the researchers and their colleagues took Sindbis virus, a related virus that causes mild fever and rash, and swapped out some of its genes for some from VEEV. The resulting hybrid virus, called Sindbis-VEEV, infects cells like authentic VEEV but is unable to cause severe disease.

Using a genetic engineering technique known as genome-wide CRISPR screening, the researchers deleted genes in mouse neuronal cells until they found one called Ldlrad3 whose absence kept Sindbis-VEEV from infecting cells. The missing gene codes for a little-studied surface protein.

Further experiments verified the importance of Ldlrad3. Adding the gene back to neuronal cells restored the viruss ability to infect cells. The human LDLRAD3 gene is almost identical to its mouse equivalent, and knocking out the human gene also reduced infection in multiple cell lines. When the researchers added Ldlrad3 to a different cell type that is normally resistant to infection, the virus was able to infect the cell. Co-author William Klimstra, PhD, at the University of Pittsburgh, separately replicated the findings using authentic, highly virulent VEEV.

Ldlrad3 doesnt appear to be the only way the virus gets inside cells, since a small amount of virus is able to infect cells lacking the protein. But it is clearly the primary way in. Since Ldlrad3 is naturally on our cells and cant be removed, the scientists decided to create a decoy handle using a piece of the Ldlrad3 protein. Any virus particles that mistakenly latch onto the decoy handle would fail to infect cells and instead would get destroyed by the immune system.

To test their decoy in a living animal, the researchers injected mice with authentic virulent VEEV in two different ways: under the skin to mimic a mosquito bite, or directly into the brain. They gave the mice the decoy handle or a placebo molecule for comparison, either six hours before or 24 hours after infection. In all experiments, all of the mice that received the placebo died within a week. In most cases, all of the mice that received the decoy molecule survived, although in the most stringent experiment in which the virus was injected into the brain two of the 10 mice died despite receiving the decoy.

In an outbreak situation, you may be able to use a drug like this as a countermeasure to prevent transmission and further spread, Diamond said.

A major advantage to an antiviral drug based on a human rather than a viral protein is that it is unlikely the virus could evolve resistance to it. Any mutation that enables the virus to avoid the decoy probably would make it unable to attach to cells, too, the researchers said.

Ma H, Kim AS, Kafai NM, Earnest JT, Shah A, Case JB, Basore K, Gilliland TC, Sun C, Nelson CA, Thackray LB, Klimstra WB, Fremont DH, Diamond MS. LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. Nature. Nov. 18, 2020. DOI: 10.1038/s41586-020-2915-3

This study was supported by the National Institutes of Health (NIH), grant numbers R01AI143673, U19AI142790, R01AI095436 and T32 AI007172 and contract number HHSN272201700060C; and the Defense Reduction Threat Agency, grant numbers HDTRA1-15-1-0013 and HDTRA1-15-1-0047.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

View post:

Lethal brain infections in mice thwarted by decoy molecule - Washington University School of Medicine in St. Louis

Our Political System Is Unfair. Liberals Need to Just Deal With It. – The New York Times

The American voters chose to give the Democrats the White House, but denied them a mandate. Even if Democrats somehow squeak out wins in both Georgia Senate races, the Senate will then pivot on Joe Manchin of West Virginia.

Not only does this take much of the liberal wish list off the table, it also makes deep structural reform of federal institutions impossible. There will be no new voting rights act in honor of the late Representative John Lewis, no statehood for Washington, D.C., and Puerto Rico, and no Supreme Court packing. For that matter, the filibuster will not be eliminated, which would have been the essential predicate for all of those other changes as well as expansive climate or health care legislation. Anything that Democrats want to do that requires a party-line vote is forlorn.

In response to this disappointment, a number of left-of-center commentators have concluded that democracy lost in 2020. Our constitutional order, they argue, is rotten and an obstacle to majority rule. The Electoral College and the overrepresentation of small, mostly conservative states in the Senate is an outrage. As Ezra Klein has argued, our constitution forces Democrats to win voters ranging from the far left to the center right, but Republicans can win with only right-of-center votes. As a consequence, liberals cant have nice things.

The argument is logical, but it is also a strategic dead end. The United States is and in almost any plausible scenario will continue to be a federal republic. We are constituted as a nation of states, not as a single unitary community, a fact that is hard-wired into our constitutional structure. Liberals may not like this, just as a man standing outside in a rainstorm does not like the fact he is getting soaked. But instead of cursing the rain, it makes a lot more sense for him to find an umbrella.

Liberals need to adjust their political strategy and ideological ambitions to the country and political system we actually have, and make the most of it, rather than cursing that which they cannot change.

There are certainly some profound democratic deficits built into our federal constitution. Even federal systems like Germany, Australia and Canada do not have the same degree of representative inequality that the Electoral College and Senate generate between a citizen living in California versus one living in Wyoming.

There is also next to nothing we can do about it. The same system that generates this pattern of representative inequality also means that short of violent revolution the beneficiaries of our federal system will not allow for it to be changed, except at the margins. If Democrats at some point get a chance to get full representation for Washington, D.C., they should take it. But beyond that, there are few if any pathways to changing either the Electoral College or the structure of the Senate. So any near-term strategy for Democrats must accept these structures as fixed.

The initial step in accepting our federal system is for Democrats to commit to organizing everywhere even places where we are not currently competitive. Led by Stacey Abrams, Democrats have organized and hustled in Georgia over the last couple of years, and the results are hard to argue with. Joe Biden should beg Ms. Abrams (or another proven organizer like Ben Wikler, the head of the party in Wisconsin) to take over the Democratic National Committee, dust off Howard Deans planning memos for a 50 state strategy from the mid-2000s and commit to building the formal apparatus of the Democratic Party everywhere.

This party-building needs to happen across the country, even where the odds seem slim, in order to help Democrats prospect for attractive issues in red states (and red places in purple states), to identify attractive candidates and groom them for higher office and to build networks of citizens who can work together to rebuild the party at the local level.

A necessary corollary of a 50 state strategy is accepting that creating a serious governing majority means putting together a policy agenda that recognizes where voters are, not where they would be if we had a fairer system of representation. That starts with an economics that addresses the radically uneven patterns of economic growth in the country, even if doing so means attending disproportionately to the interests of voters outside of the Democrats urban base. That is not a matter of justice, necessarily, but brute electoral arithmetic.

That does not mean being moderate, in the sense of incremental and toothless. From the financialization of our economy to our constrictive intellectual property laws to our unjust tax competition between states for firms, the economic deck really is stacked for the concentration of economic power on the coasts. Democrats in the places where the party is less competitive should be far more populist on these and other related issues, even if it puts them in tension with the partys megadonors.

We also need to recognize that the cultural values and rituals of Democrats in cosmopolitan cities and liberal institutional bastions like universities do not seem to travel well. Slogans like defund the police and abolish ICE may be mobilizing in places where three-quarters of voters pull the lever for Democrats. But it is madness to imagine that they could be the platform of a competitive party nationwide.

That doesnt mean that we should expect members of the Squad not to speak out for fear of freaking out the small town voters that Democrats like Representative Abigail Spanberger of Virginia represent. But it does mean recognizing that, unlike the more homogeneous Republicans, the Democrats have no choice but to be a confederation of subcultures. We need to develop internal norms of pluralism and coexistence appropriate to a loose band of affiliated politicians and groups, rather than those of a party that is the arm of a cohesive social movement.

The Democratic Party has a future within the constitution the country has. The question for the next decade is, will we withdraw into pointless dreams of sweeping constitutional change or make our peace with our country and its constitution, seeking allies in unlikely places and squeezing out what progress we can get by organizing everywhere, even when the odds of success seem slim.

Steven Teles, a political science professor at Johns Hopkins University and a senior fellow at the Niskanen Center, is an author, with Robert Saldin, of the book Never Trump: The Revolt of the Conservative Elites.

Read the rest here:

Our Political System Is Unfair. Liberals Need to Just Deal With It. - The New York Times

Liberals Envisioned a Multiracial Coalition. Voters of Color Had Other Ideas. – The New York Times

The proposition seemed tailor-made for one of the nations most diverse and liberal states. California officials asked voters to overturn a 24-year-old ban on affirmative action in education, employment and contracting.

The state political and cultural establishment worked as one to pass this ballot measure. The governor, a senator, members of Congress, university presidents and civil rights leaders called it a righting of old wrongs.

Women and people of color are still at a sharp disadvantage by almost every measure, The Los Angeles Times wrote in an editorial endorsement.

Yet on Election Day, the proposition failed by a wide margin, 57 percent to 43 percent, and Latino and Asian-American voters played a key role in defeating it. The outcome captured the gap between the vision laid out by the liberal establishment in California, which has long imagined the creation of a multiracial, multiethnic coalition that would embrace progressive causes, and the sentiments of many Black, Latino, Asian and Arab voters.

Variations of this puzzle could be found in surprising corners of the nation on Election Day, as slices of ethnic and racial constituencies peeled off and cut against Democratic expectations.

We should not think of demography as destiny, said Professor Omar Wasow, who studies politics and voting patterns at Princeton University. These groups are far more heterogeneous than a monolith and campaigns often end up building their own idiosyncratic coalition.

Asian-American Californians opposed the affirmative action measure in large numbers. A striking number of East and South Asian students have gained admission to elite state universities, and their families spoke to reporters of their fear that their children would suffer if merit in college selection was given less weight. That battle carried echoes of another that raged the past few years in New York City, where a white liberal mayors efforts to increase the number of Black and Latino students in selective high schools angered working- and middle-class South and East Asian families whose children have gained admission to the schools in large numbers.

Theres more texture to California blue politics than you might think, said Lanhee Chen, a fellow at the conservative Hoover Institution at Stanford University and policy director for Mitt Romneys 2012 presidential run. Identity politics only go so far. There is a sense on affirmative action that people resent being categorized by progressives.

Latinos, too, appear sharply divided. Prominent Latino nonprofit and civil rights organizations endorsed the affirmative action proposition even as all 14 of Californias majority-Latino counties voted it down.

Latinos make up more than half of San Bernardino Countys population, although significantly fewer turn out to vote. More residents there voted on the affirmative action proposition than for president, rejecting it by a margin of 28 percentage points. In rural Imperial County, in the southeastern corner of the state, 85 percent of the population is Latino. The voters there who gave Joseph R. Biden Jr. a nearly 27-point margin of victory went against the affirmative action measure by 16 percentage points.

The results suggest that Democrats may need to adjust their strategy as the complexities of class, generation and experience, and the competing desires of these demographic groups become clear. Since the dawn of the 21st century, it has become commonplace for party leaders to talk of a rising demographic tide that is destined to lift the Democrats to dominance. That liberal coalition is seen as resting on a bedrock of upper-middle-class white voters, alongside working- and middle-class Black, Latino and Asian voters.

In broad strokes, that narrative held. Black voters, along with a shift in the white suburban vote, played a pivotal role in delivering Georgia to the Democratic column (although so closely that a statewide audit is taking place). So, too, Black voters in Pittsburgh and Philadelphia voted overwhelmingly for Democrats as did well-to-do majority-white suburbs and gave Pennsylvania and therefore the national election to President-elect Biden.

In Arizona, Latino voters piled up large margins for Mr. Biden and tipped the state narrowly into the Democratic column for the first time since 1996. Representative Ruben Gallego, the Democratic congressman from Phoenix who is a former Marine and a Harvard graduate, noted that several decades of aggressive tactics by Republican governors and white sheriffs had stirred activism among the young Latinos who dominate politics there.

The Republicans caught Latino lightning in the bottle in Florida and South Texas, but not here, Mr. Gallego said. We are very politicized. Its just important that white liberals dont impose their thoughts and policies on us.

Aside from those successes, however, the election presented complications wrapped one inside another for Democrats. In Texas and Florida, in California and in Colorado (where New York Times exit polls found that roughly 40 percent of white voters and 38 percent of Latino voters cast ballots for President Trump), the assumption that people of color would vote as a liberal Democratic bloc often proved illusory.

John Judis is a liberal writer and scholar who in 2002 co-wrote The Emerging Democratic Majority, which became a seminal text for those who saw the Democratic Party as a political tide rising. He has since backed off that a touch.

People of color is a term thats been adopted by the cultural left as a way of arguing that if these groups proportionately voted Democratic in the past, they will do so in the future, Mr. Judis said. I dont see how you can make the argument.

Viewing the Latino vote as monolithic fails, of course, to capture the often sharply varying politics and ethnicities of people hailing from nearly two dozen countries on two continents. The same is true when examining the behavior of Asian-American voters.

Philadelphia offers a snapshot: A record number of Latinos in the city, which is heavily Puerto Rican and Dominican, turned out and buoyed Mr. Biden. Yet exit polls also found that Latino voter support there for Mr. Trump leapt to 35 percent this year from 22 percent in 2016. In Milwaukee, an analysis by Urban Milwaukee reported an uptick in the Latino working-class vote for Mr. Trump, although a majority still favored Mr. Biden.

Along the Rio Grande in Texas, where some Mexican-American families, known as Tejanos, have roots that extend back four centuries, the vote margins shifted dramatically in 2020. Latino turnout soared, almost entirely to the benefit of Mr. Trump. Although Mr. Biden obtained more total votes in the four counties of the Rio Grande Valley than Hillary Clinton did in 2016, his margins of victory fell sharply.

The reasons offered for these results include poor field organizing by the Democratic Party, the cultural conservatism of some older Tejano families, and the fact that many in these often-dense counties find good-paying jobs with the Border Patrol.

Many voters, too, worried that Mr. Biden and the Democrats would impose a new coronavirus-driven shutdown, with dire consequences for the many thousands who own and labor for small businesses. Prof. Omar Valerio-Jimenez grew up in the Rio Grande Valley and teaches history at the University of Texas at San Antonio. Several of his old friends and cousins voted for Mr. Trump.

They faced this challenge: Do they continue to open our stores and restaurants and churches, which lets us pay our bills, he said, or do we quarantine and not have the money to pay our bills?

Muslim voters also confounded Democratic strategists with their support for Mr. Trump reaching 35 percent, according to The Associated Press. This, too, is a constituency difficult to pigeonhole, as it encompasses Africans, Arabs, South Asians and Europeans.

A sizable number of Muslims have experienced Donald Trump and to the surprise of Democrats they said, We want more of that, Shadi Hamid of the Brookings Institution said.

Analyzing vote shifts is a tricky business, particularly when trying to gauge why some Latino, Black or Arab voters moved from supporting a liberal Democratic candidate like Mrs. Clinton in 2016 to voting for a populist authoritarian Republican like Mr. Trump. Some analysts pointed to the appeal among male voters regardless of color or ethnicity of Mr. Trumps masculine persona. Others mentioned the performance of the national economy, which had hummed along until the plague arrived.

There were small, intriguing changes in the Black vote as well. The Timess exit polls in Georgia found that 16 percent of Black men voted for Mr. Trump. (Compared with 7 percent of Black women there.) And to chart the votes along the so-called Black Belt in Mississippi, which includes 10 counties along the Mississippi River, was to find that although Mr. Biden won handily, his margin in nearly every county was two to three percentage points smaller than Mrs. Clintons.

The unanswered question is whether the 2020 election will be a one-off, the voting patterns scrambled by an unusually polarizing president who attracted and repelled in near equal measure. If it signals something larger, political scientists noted, some Latino and Asian voters might begin to behave like white voters, who have cleaved along class lines, with more affluent residents in urban areas voting Democratic while a decided majority of rural and exurban residents support Republicans.

Then there is California, where the sands of change blow in varying directions. In 2018, Democrats swept the Orange County congressional seats. In 2020, the Republicans have rebounded and taken at least two of those seats.

The Republican candidate Michelle Steel, who is Korean-American, came out against the affirmative action proposition, a stance that proved popular with her Asian-American constituents, as well as many white voters. And on election night, Ms. Steel rode that support to a narrow win against the incumbent Democratic congressman, Harley Rouda.

This is the challenge for liberal Democrats, Professor Wasow said. In a diverse society, how do you enact politics that may advance racial equality without reinforcing racial divisions that are counterproductive and hurt you politically?

View post:

Liberals Envisioned a Multiracial Coalition. Voters of Color Had Other Ideas. - The New York Times

Neal Gabler with Catching the Wind: Edward Kennedy and the Liberal Hour, 1932-1975 (Virtual) – wgbh.org

"Catching the Wind" is the first volume of Neal Gablers two-volume biography of Edward Kennedy. It is at once a human drama, a history of American politics in the late twentieth and early twenty-first centuries. Though he is often portrayed as a reckless hedonist who rode his fathers fortune and his brothers coattails to a Senate seat at the age of thirty, the Ted Kennedy in "Catching the Wind" is one the public seldom saw. He entered the Senate with his colleagues lowest expectations, a show horse, not a workhorse, but he used his ninth-childs talent of deference to and comity with his Senate elders to become a promising legislator. And with the deaths of his brothers John and Robert, he was compelled to become something more: the custodian of their political mission.

BPL President David Leonard will moderate this program, part of the Arc of History: Contested Perspectives series.

This conversation is part of the esteemed Lowell Lecture Series at the Boston Public library and is produced by GBHs Forum Network.

This virtual event will begin at 6pm Eastern Standard Time.

Forum Network events are free and available to the public, but you must register for webinar access.

GBH encourages you to use Zoom Webinar to watch for this event. Zoom is free to the public but you will need to download it to your computer first. You can download Zoom here. If you already have Zoom, you will not need to download the platform again.

Read the original:

Neal Gabler with Catching the Wind: Edward Kennedy and the Liberal Hour, 1932-1975 (Virtual) - wgbh.org

Opposition defeats Liberals on motion to fight Chinese tactics – The Globe and Mail

A woman browses her smartphone by the Huawei retail shop in Beijing on Oct. 11, 2020.

Andy Wong/The Associated Press

Opposition parties joined forces Wednesday to pass a motion calling on the minority Liberal government to unveil a comprehensive plan within 30 days to fight Chinese state-sponsored harassment and interference against Canadians.

In a rare government defeat in the House, the Conservative motion also called on the government to announce within 30 days whether equipment made by Chinas Huawei Technologies Co Ltd. would be allowed in Canadas 5G wireless networks. This is a question Ottawa has been studying for more than two years.

Although not binding, the motion, which passed 178 to 146, functions as a declaration of support or purpose. The governing Liberals mostly voted against the motion, aside from a handful including Beaches-East York MP Nathaniel Erskine-Smith and Scarborough-Guildwood MP John McKay.

Story continues below advertisement

The Conservatives, Bloc Qubcois, NDP and other MPs voted in favour. Not all MPs registered a vote.

Conservative foreign affairs critic Michael Chong said the Commons vote is a sign that Canadians want action.

Canadians expect the Liberal government to uphold our democratic norms and respect the will of Parliament by taking action to defend Canadas national security and make a decision on Huawei and Canadas 5G network, he said, and by developing a plan to protect Canadians against Communist Chinas growing influence operations here at home.

In responding to the vote, the Liberal government made no commitment to bring forward a plan to further combat Chinese interference and said it requires more time to consider whether to exclude any gear from this countrys 5G networks.

It is unacceptable for China to interfere in domestic affairs here in Canada as is any intimidation of Canadians, including those of Chinese origin, a spokeswoman for Foreign Affairs Minister Franois-Philippe Champagne said.

Press secretary Syrine Khoury said the Liberals felt they could not support a motion calling for a decision on Huawei within 30 days because Ottawa is still studying how best to protect Canadian telecommunication networks without stifling innovation.

Cheuk Kwan, former chair of the Toronto Association for Democracy in China, lauded the opposition parties for taking a stand and criticized Prime Minister Justin Trudeau and his Liberal caucus for voting against the motion.

Story continues below advertisement

The Liberals have for many years not had a backbone to stand up to China, he said. There is no excuse any more. How many more months or years are you going to study the Huawei situation and how many more years [do we] have to tolerate this Chinese influence and interference in our lives?

Mr. Kwan said some of Canadas allies have banned Huawei from their 5G networks and he urged the government to follow Australias tougher approach to Beijing.

Australia has not only joined the U.S. in banning Huaweis 5G gear but enacted tough measures to counter Chinese state intimidation and interference in that countrys immigrant community.

They have done a wonderful of job of recognizing the situation and instituting hard, aggressive legislation to respond to Chinese interference, he said, including a federal registry to shed light on the work individuals are doing on behalf of China and other foreign states.

The motion came one week after The Globe and Mail reported that the Canadian Security Intelligence Service warned that Chinese state-sponsored harassment in Canada is part of a global campaign of intimidation that constitutes a threat to this countrys sovereignty and the safety of Canadians.

Last week, Mr. Trudeau told reporters recently we have seen an intensification of the aggressive and coercive diplomatic approach on the part of China.

Story continues below advertisement

Gloria Fung, president of Canada-Hong Kong Link, said her organization was pleased this motion passed because it shows there is a really strong urge in Canada for concrete action to be taken by our government to address all these major threats from China, including Huawei.

The Chinese Communist Party has been taking a very arrogant approach in intimidating and harassing Canadians they have also conducted a lot of espionage and infiltration here, she said.

Cherie Wong, executive director of Alliance Canada Hong Kong, said she remains hopeful that the Trudeau government will take the motion seriously. She added that, in recent months, Ottawa has suspended an extradition treaty with Hong Kong, banned weapons sales to the former British colony and opened the door to more Hongkongers becoming Canadian citizens.

But Ms. Wong said the Liberals can no longer sit on the sidelines, as agents of Chinas Communist Party make blatant attempts to threaten critics of the regime a campaign she says is widespread.

There is regular surveillance on Chinese Canadians but the surveillance they exert on Uyghurs, Tibetans and Hongkongers are at a different level, she said. Over the past few years, the harassment campaigns have actually targeted specifically on Uyghurs and Tibetans as well as mainland Chinese whose families are back in China.

Ottawa is being urged to set up a dedicated national hotline where individuals and groups can report intimidation or harassment by agents of China. In addition, CSIS and the RCMP are being encouraged to hold a continuing dialogue with community groups about the various methods that China uses to silence dissent among Hong Kong Canadians and those from mainland China, including Uyghurs and Tibetans.

Story continues below advertisement

Alykhan Velshi, vice-president of corporate affairs for Huawei Canada, declined to say whether his company wanted a decision within 30 days. Huawei has always supported, and continues to support, the Canadian governments evidence-based review of potential 5G providers.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the days most important headlines. Sign up today.

Read the original post:

Opposition defeats Liberals on motion to fight Chinese tactics - The Globe and Mail